YOLFTbeta
11

KPX Lifescience.Co.Ltd

114450 · KQ · Healthcare / Pharmaceuticals

2,100.00KRW+35.00 (+1.69%)

Price History

Full chart

Market Stats

Previous Close2,065.00
Open2,100.00
Day Range2,070.00 – 2,260.00
52-Week Range1,673.00 – 4,590.00
Volume140.17K
Market Cap46.00B
P/E (TTM)0.00
Forward P/E0.00
Dividend Yield0.00%
Beta1.30
50-Day Avg2,237.30
200-Day Avg2,576.01

About

KPX Lifescience.Co.,Ltd. engages in development, production, and sale of agrochemical raw materials and pharmaceutical intermediates in South Korea and internationally. The company offers raw materials for pharmaceuticals, pesticides, and primary intermediates to the pharmaceutical and agrochemical markets. It also develops EDP-CL, an intermediate for piperacillin-based antibiotics, including N,N-disuccinimidyl carbonate used for the synthesis of HIV treatment; Amoxapine, an antidepressant raw material; and AM19, an antibiotic intermediate. The company was formerly known as MNH Laboratories Co., Ltd. and changed its name to KPX Lifescience.Co.,Ltd. in September 2008. The company was founded in 2005 and is headquartered in Yeosu, South Korea. KPX Lifescience.Co.,Ltd. is a subsidiary of KPX Holdings Co., Ltd.

Company Details

  • SectorHealthcare
  • IndustryPharmaceuticals
  • CEOJun-Yeong Yang
  • Employees0
  • Headquarters84, Yeosusandan 2-ro, Yeosu-Si, South Korea, Korea
  • Websitehttps://www.kpxls.com

Leadership

  • Jun-Yeong YangChief Exec. Officer · b. 1969
  • Ui-Nam GwakChief Exec. Officer · b. 1953

Financials

Income Statement

Currency: KRW2014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue37.08B45.51B43.30B42.58B32.75B37.62B24.56B25.34B36.50B22.37B24.86B40.34B
Growth (%)-+22.73%-4.84%-1.66%-23.09%+14.85%-34.71%+3.16%+44.07%-38.72%+11.14%+62.26%
Cost of Revenue36.52B37.72B35.92B37.94B32.68B34.59B24.64B27.61B37.86B24.68B21.88B37.87B
Gross Profit561.19M7.79B7.39B4.65B70.81M3.03B-74.62M-2.27B-1.36B-2.31B2.98B2.47B
Gross Margin1.51%17.12%17.06%10.91%0.22%8.06%-0.30%-8.96%-3.72%-10.33%11.99%6.12%
Operating Expense2.39B2.25B2.35B2.24B2.02B2.44B1.83B2.38B2.60B14.43B2.60B2.26B
Operating Income-1.83B5.55B5.03B2.41B-1.95B591.10M-1.91B-4.65B-3.96B-16.74B376.91M204.29M
Operating Margin-4.94%12.19%11.62%5.65%-5.96%1.57%-7.77%-18.35%-10.84%-74.82%1.52%0.51%
EBITDA--------21.93M-13.64B2.57B1.14B
EBITDA Margin--------0.06%-60.98%10.33%2.83%
Net Income-1.06B5.39B4.50B2.22B-1.45B1.20B-1.06B-3.14B-3.53B-16.36B1.56B110.13M
Net Income Margin-2.86%11.84%10.40%5.22%-4.41%3.18%-4.31%-12.38%-9.66%-73.13%6.28%0.27%
R&D-------109.59M425.82M112.11M734.99M292.17M
R&D as % of Total Revenue-------0.43%1.17%0.50%2.96%0.72%
Interest Expense00000018.87M22.20M113.34M240.43M238.06M242.17M
Interest Expense % of Total Revenue0.00%0.00%0.00%0.00%0.00%0.00%0.08%0.09%0.31%1.07%0.96%0.60%

Balance Sheet

Currency: KRW2014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets66.43B67.15B77.06B72.96B69.37B71.89B70.85B71.98B62.43B43.83B44.97B54.86B
Total Liabilities14.90B10.25B15.39B10.87B10.26B11.54B11.48B15.68B9.79B7.87B9.22B16.58B
Total Equity51.53B56.90B61.66B62.09B59.11B60.36B59.37B56.30B52.64B35.95B35.75B38.29B
Cash3.08B3.43B7.03B1.92B523.86M7.51B2.40B3.39B2.81B6.35B9.07B13.41B
Total Debt------6.24B-----
Net Debt------3.81B4.04B3.67B---

Cash Flow

Currency: KRW2014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow4.09B5.62B7.07B5.68B5.38B4.24B1.90B611.38M-4.55B370.02M525.49M363.85M
Investing Cash Flow-661.30M-1.64B-4.61B-5.19B-6.23B2.92B-7.89B-602.00M5.06B7.52B3.28B-
Financing Cash Flow-1.10B-3.62B1.05B-5.70B-546.36M-182.25M899.98M961.34M-1.07B-4.31B-1.93B-
Capital Expenditure838.78M526.82M1.60B4.31B7.49B3.60B2.67B3.44B1.48B475.02M462.71M1.16B
Free Cash Flow------943.30M-765.10M-2.83B-6.03B-105.00M62.78M-796.37M
Dividends Paid2.01B2.01B2.01B2.01B1.50B-------
FCF to OCF------22.24%-40.22%-463.25%132.47%-28.38%11.95%-218.87%

Earnings

Report DateMar 31, 2010Jun 30, 2010Sep 30, 2010Dec 31, 2010Mar 31, 2011Jun 30, 2011Sep 30, 2011Dec 31, 2011Mar 31, 2012Jun 30, 2012Sep 30, 2012Dec 31, 2012Mar 31, 2013Jun 30, 2013Sep 30, 2013Dec 31, 2013Mar 31, 2014Jun 30, 2014Sep 30, 2014Dec 31, 2014Mar 31, 2015Jun 30, 2015Sep 30, 2015Dec 31, 2015Mar 31, 2016Jun 30, 2016Sep 30, 2016Dec 31, 2016Mar 31, 2017Jun 30, 2017Sep 30, 2017Dec 31, 2017Mar 31, 2018Jun 30, 2018Sep 30, 2018Dec 31, 2018Mar 31, 2019Jun 30, 2019Sep 30, 2019Dec 31, 2019Mar 31, 2020Jun 30, 2020Sep 30, 2020Dec 31, 2020Mar 31, 2021Jun 30, 2021Sep 30, 2021Dec 31, 2021Mar 31, 2022Jun 30, 2022Sep 30, 2022Dec 31, 2022Mar 31, 2023Jun 30, 2023Sep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
EPS Estimate------------------------------------------------------------------
EPS Actual56.0365.5258.2353.2397.14-23.1635.9851.5231.0319.4380.15-9.189.7016.35-23.08-68.56-5.42-11.744.56-40.4936.8354.1463.91115.7649.2354.4374.6546.9085.9612.8758.32-45.9122.40-13.166.31-87.8117.1223.6517.002.01-35.6738.06-4.82-50.56-25.39-15.62-39.19-76.605.21-24.25-17.70-139.54-44.16-51.48-23.75-704.4153.9170.57-56.8713.30-60.021.8925.6838.1988.46220.21
Surprise------------------------------------------------------------------
Timing------------------------------------------------------------------

Key Statistics & Ratios

Market Cap46.00B
Enterprise Value29.89B
Trailing P/E0.00
Forward P/E0.00
Price / Sales0.70
Price / Book0.98
Revenue (TTM)39.98B
Gross Profit (TTM)-2.27B
EBITDA-1.08B
Profit Margin-5.67%
Operating Margin-9.55%
Return on Equity-181.82%
Return on Assets-3.53%
Shares Outstanding15.00M
Shares Float11.06M
Beta1.30
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Dividends

20172×
75.00Dec 27, 2017100.50Jun 29, 2017
20131×
100.00Jun 27, 2013
20122×
375.00Dec 27, 201275.00Jun 28, 2012
20112×
93.75Dec 28, 201175.00Jun 29, 2011
20102×
93.75Dec 29, 201056.25Jun 29, 2010
20091×
112.50Dec 29, 2009

Stock Splits

  • Sep 5, 20234:3